FDA Approves Dectomax-CA1 for Treatment and Prevention of NWS Infestations in Cattle
U.S. Food and Drug Administration (FDA) shared on LinkedIn:
”Today, we conditionally approved the first drug for the prevention and treatment of New World screwworm (NWS) larval infestations as well as the prevention of NWS reinfestation for 21 days.
This conditional approval is limited for use in cattle and demonstrates the Agency’s dedication to rapidly facilitating access to important animal health products.”
New World Screwworm infestations, first re-emerging in Central America in 2024, have spread north through Mexico in 2025, with cases now detected as far as Nuevo Leon near the U.S. border.
The outbreak threatens regional cattle industries, prompting livestock movement restrictions, sterile fly release programs, and strict U.S.–Mexico border surveillance.
On September 30, 2025, the U.S. Food and Drug Administration conditionally approved Dectomax-CA1 for the prevention and treatment of New World screwworm (NWS) larval infestations in cattle.
The drug is available as an injectable solution and provides protection against reinfestation for up to 21 days.
Doramectin, the active ingredient, is a macrocyclic lactone that targets the parasite’s nervous system by selectively binding to glutamate-gated chloride channels.
This binding leads to hyperpolarization of nerve and muscle membranes, resulting in paralysis and death of the parasite.
Its longer half-life, due to greater lipophilicity and enhanced tissue distribution, underlies its prolonged activity, which represents a key advantage over other similar agents.
Read more on the topic here.

More on latest FDA approvals in the field of Hematology featured in Hemostasis Today.
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:18Thomas Dayspring: Prognostic Impact of Lp(a) Changes Following Statin Therapy in Patients with CAD
-
Aug 26, 2026, 14:17Khurram Nasir: Are We Debating the Wrong Thing About Research in Medical Training?
-
Aug 26, 2026, 14:15Nathan Connell: Why Format Free Publishing Still Demands Formatting?
-
Aug 26, 2026, 14:14Reza Shojaei: China’s Reliance on Imported Albumin Raises Global Plasma Security Concerns
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM